MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
GT Biopharma ROE Ratio 2011-2026 | GTBP
Annual ROE Ratio GT Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -489.96 | 788.14 | -101.62 | -177.98 | -264.78 | 96.14 | 200.14 | -2279.56 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 788.14 | -2279.56 | -278.68 |
Quarterly ROE Ratio GT Biopharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -237.36 | -296.23 | -313.49 | -272.68 | -296.82 | -158.31 | -107.89 | -42.82 | -85.95 | -104.93 | -107.29 | -93.0 | -110.11 | -84.09 | -78.19 | -154.07 | -144.3 | -117.42 | -44.83 | 74.77 | 229.49 | 374.45 | 329.7 | 192.53 | -1881.2 | -4109.66 | -4203.97 | -2242.35 | -2294.25 | -272.42 | -193.53 | -54.89 | -35.71 | 35.38 | 28.2 | -66.57 | -63.22 | -79.06 | -124.02 | -9.2 | 5.07 | 15.99 | 69.99 | 16.41 | 21.45 | 12.21 | 16.36 | 2.68 | 24.78 | 41.84 | 74.6 | 69.6 | 69.15 | 46.6 | 21.78 | 50.23 | -0.45 | 12.98 | 37.7 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 374.45 | -4203.97 | -281.46 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M |  USA |
 |
Veracyte
VCYT
|
5.07 | $ 30.92 | -5.73 % | $ 2.43 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-231.16 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-27.19 | $ 12.67 | -9.24 % | $ 1.92 B | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 321.51 | -2.03 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-63.65 | $ 1.09 | - | $ 22.4 M | Israel |
 |
Enochian Biosciences
ENOB
|
833.76 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
-78.32 | $ 1.91 | -7.28 % | $ 109 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.46 | -0.36 % | $ 910 M | USA |
 |
Amarin Corporation plc
AMRN
|
-8.45 | $ 14.23 | -2.97 % | $ 5.91 B |  Irlanda |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 45.99 | -3.28 % | $ 4.14 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.33 | -2.81 % | $ 830 M | Canada |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |